Cancer Cell International, published by BMC, is a transformative open-access journal established in 2001, dedicated to advancing the field of oncology and cancer research. With its ISSN number not specified and an E-ISSN of 1475-2867, the journal proudly operates from the United Kingdom, located at CAMPUS, 4 Crinan St, London N1 9XW, England. Renowned for its rigorous peer-review process, Cancer Cell International has made significant strides, securing a Q2 ranking in Cancer Research and Q1 rankings in both Genetics and Oncology as of 2023. It ranks impressively in Scopus, featuring in the top quintile of Genetics (#37/347) and Oncology (#52/404), indicating its importance within the scientific community. The journal's broad scope caters to a diverse array of topics within cancer biology, making it an invaluable resource for researchers, professionals, and students seeking to stay at the forefront of cancer science. With a commitment to disseminating high-quality research, Cancer Cell International invites scholars to explore innovative findings and contribute to the collective effort of combating cancer.

Rheumatology & Autoimmunity, published by WILEY, is an emerging academic journal that delves into the intricacies of rheumatological diseases and autoimmune disorders, providing a critical platform for researchers and practitioners within the field. With an ISSN of 2767-1410 and E-ISSN 2767-1429, the journal aims to disseminate cutting-edge research in both clinical and laboratory settings, enhancing knowledge and understanding among professionals and scholars. Although currently classified in Q4 for Immunology and Allergy, and Q3 for Internal Medicine and Rheumatology as of 2023, the journal is positioned for growth and greater visibility in the scientific community. The three-year publishing span from 2021 to 2024 signifies a commitment to addressing contemporary issues and fostering collaboration among various disciplines related to immunology. As an open access journal, it provides wide accessibility, ensuring that groundbreaking research is available to a broad audience. This journal is poised to become a vital resource for those dedicated to advancing the understanding and treatment of autoimmune conditions.

ALLERGY is a leading international journal published by WILEY, dedicated to advancing the understanding of allergic diseases and immunology. With an ISSN of 0105-4538 and an E-ISSN of 1398-9995, this esteemed journal has been at the forefront of the field since its inception in 1948 and continues to publish high-quality research up until 2024. Positioned in the Q1 category for both Immunology and Allergy, ALLERGY ranks impressively within the top percentiles of its categories, underscoring its significant impact, as reflected in its Scopus rankings (#11 out of 233 in Immunology and Allergy, and #14 out of 236 in Immunology and Microbiology). Researchers and practitioners accessing this journal can expect a rigorous selection of peer-reviewed articles that address current challenges, innovative therapies, and advancements in the immunological sciences. Although it is not an open-access journal, ALLERGY remains vital for academics, healthcare professionals, and students alike, fostering a deeper understanding of the mechanisms and treatments associated with allergies.

CELL BIOLOGY AND TOXICOLOGY, published by SPRINGER, stands as a vital journal within the realms of cell biology and toxicology, boasting an impressive 2023 Q1 ranking in its fields, alongside robust Scopus rankings placing it in the top 11th percentile for Toxicology and the 22nd for Health, Toxicology and Mutagenesis. With an ISSN of 0742-2091 and an E-ISSN of 1573-6822, the journal has been a cornerstone of scientific discourse since its inception in 1984, and will continue to converge innovative research until 2024. The journal focuses on the interplay between cellular mechanisms and toxicological implications, making it an essential resource for researchers, healthcare professionals, and students keen on advancing their understanding of these critical areas. Although it does not offer open access, its high impact and prestigious standing ensure that its publications reach a wide audience dedicated to significant advancements in the life sciences.

Molecular Medicine Reports, an esteemed academic journal published by Spandidos Publications Ltd, serves as a vital platform for the dissemination of cutting-edge research in the field of molecular medicine. Established in 2008, this journal has rapidly ascended in prominence, currently positioned within the Q2 and Q3 quartiles across various critical categories including Biochemistry, Cancer Research, and Genetics, reflecting its significant impact and scholarly contributions. With an impressive Scopus ranking in multiple disciplines, including an 87th place in Oncology, it is recognized for publishing rigorous, peer-reviewed articles that bridge the gap between laboratory research and clinical applications. The journal’s commitment to advancing knowledge in molecular medicine is evident through its focus on innovative therapeutic approaches, genetic research, and oncological studies, catering to a diverse readership of researchers, professionals, and students in the biomedical field. Though not an open-access publication, it provides invaluable insights and fosters collaboration in the scientific community from its base in Athens, Greece.

Allergy Asthma & Immunology Research, published by the Korean Academy of Asthma Allergy & Clinical Immunology, is a leading journal dedicated to advancing the fields of immunology, allergy, and respiratory medicine. With an ISSN of 2092-7355 and an E-ISSN of 2092-7363, this esteemed publication has been a cornerstone for researchers and practitioners since its inception in 2009 and continues to disseminate critical findings through till 2024. The journal is ranked in the Q3 category in Immunology and the Q2 category in Immunology and Allergy as well as Pulmonary and Respiratory Medicine, illustrating its impact in these vital fields. With a solid Scopus ranking in multiple sub-disciplines, the journal not only contributes to the scientific discourse but also promotes innovative research and clinical practices. Although currently operating without an open access model, the journal remains highly regarded for its thorough peer-review process and commitment to academic excellence, making it an essential resource for professionals, researchers, and students passionate about advancing knowledge in allergy, asthma, and immunology.

Rheumatology International, published by Springer Heidelberg, is a prestigious journal that focuses on innovative research in the field of rheumatology and immunology. Established in 1981, this peer-reviewed journal has contributed significantly to advancing our understanding of autoimmune disorders, clinical approaches, and therapeutic interventions. It holds a commendable Q2 ranking in the categories of Immunology, Immunology and Allergy, and Rheumatology as of 2023, showcasing its influence and importance within these disciplines. With a robust Scopus ranking—positioned 14 out of 73 in Medicine Rheumatology—it caters to a diverse audience of researchers, clinicians, and students committed to improving patient care and treatment modalities. Although it does not currently offer open access options, the journal remains a vital resource for insights on contemporary challenges and breakthroughs in rheumatological research, published from its base in Heidelberg, Germany.

JOURNAL OF MOLECULAR MEDICINE (JMM) is a premier publication dedicated to advancing the field of molecular medicine, encompassing critical areas such as drug discovery, genetics, and biochemistry. Published by Springer Heidelberg in Germany, this influential journal has established its significance within the academic community, achieving an impressive Q1 ranking across multiple categories as of 2023, including Drug Discovery, Clinical Genetics, and Molecular Medicine. With a focus on publishing high-quality research and novel insights, JMM appeals to a diverse audience of researchers, professionals, and students passionate about the molecular underpinnings of health and disease. The journal, which has seen a convergence of relevant research spanning from 1976 to 2024, is instrumental in showcasing groundbreaking studies that push the boundaries of knowledge in molecular therapeutics and biomedical science. While it does not offer open access, the rigor of its peer-reviewed content ensures that each publication is a valuable addition to the scientific discourse surrounding molecular medicine. For comprehensive studies and reviews that highlight the intersection of molecular biology and clinical application, look no further than JOURNAL OF MOLECULAR MEDICINE.

Journal of Clinical and Translational Hepatology is an esteemed publication dedicated to advancing the field of hepatology through innovative research and clinical insights. Published by XIA & HE PUBLISHING INC, this journal connects researchers and healthcare professionals in the exploration of liver diseases and their management. With an impact factor that reflects its significant contribution to the discipline, the Journal holds a commendable Q2 classification in Hepatology as of 2023, and it ranks highly in both Gastroenterology and Hepatology categories on Scopus, positioning it within the top 80th percentile of its field. Although the journal is not open access, it provides its audience with invaluable information, encouraging collaboration that aims to translate clinical findings into transformative patient care. With a publication history spanning from 2013 to 2024, the Journal of Clinical and Translational Hepatology has established itself as a vital resource for researchers, clinicians, and students alike, making it a prominent voice in the hepatological community.

The Journal of Translational Autoimmunity, published by ELSEVIER, stands at the forefront of research in the ever-evolving fields of autoimmunity and immunology. With an ISSN of 2589-9090, this Open Access journal has been committed to facilitating the dissemination of high-quality research since its inception in 2019. Nestled in the Netherlands, it serves as a vital platform for researchers and professionals focused on translating innovative findings into practical applications for autoimmune disorders. The journal has achieved notable recognition, securing a Q2 quartile ranking in both the Immunology and Immunology and Allergy categories, showcasing its influence within the academic community, currently ranking 70th out of 233 in Medicine: Immunology and Allergy and 83rd out of 236 in Immunology and Microbiology: Immunology. By engaging with cutting-edge studies and fostering collaborative research, the Journal of Translational Autoimmunity is not only a cornerstone of academic inquiry but also a beacon of hope for clinical advancements in the management of autoimmune conditions. Researchers, professionals, and students alike are encouraged to contribute and stay abreast of the latest discoveries that hold the potential to transform patient care.